Atorvastatin calcium: CONCLUSIONS(3)
The safety profile of atorvastatin is comparable with that of other HMG-CoA reductase inhibitors. Atorvastatin is generally well tolerated, and adverse reactions have usually been mild and transient. As with the other HMG-CoA reductase inhibitors, the most frequent adverse events reported for ator-vastatin were constipation, flatulence, dyspepsia and abdominal pain.
From a cost perspective, the pricing of atorvastatin, together with its greater effectiveness compared with other HMG-CoA reductase inhibitors, suggests that atorvastatin may provide economic benefit. Atorvastatin provides the lowest cost per percentage of LDL-C lowering compared with other HMG-CoA reductase inhibitors. Recent economic analyses demonstrate that the direct costs (physician visits, lipid measurements, drug costs) of treating patients with ator-vastatin to treatment goals are significantly lower than those of other HMG-CoA reductase inhibitors. Inclusion of atorvas-tatin in pharmacoeconomic models evaluating lifetime cost effectiveness in primary or secondary prevention suggests atorvastatin to be the most cost effective treatment compared with other available HMG-CoA reductase inhibitors. ventolin inhalers